Skip to main content
SpringerLink
Log in

Prevention and treatment of NSAID-induced gastroduodenal injury

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

NSAIDs increase the risk of gastrointestinal (GI) complications. Those at risk should be considered for alternatives to NSAID therapy, modifications of risk factors, and prevention strategies with co-therapy with gastroprotective agents (proton-pump inhibitors [PPIs] or misoprostol) or COX-2 selective inhibitors (coxibs). Since coxibs, and probably other nonselective NSAIDs, may increase the risk of cardiovascular events, prevention strategies must take into account both GI and cardiovascular risk factors. All NSAIDs and coxibs should be prescribed at the lowest possible dose and for the shortest period of time. In patients with GI risk factors but no cardiovascular risk, coxibs or NSAIDs plus PPI or misoprostol are valid options. Patients with a history of ulcer bleeding should receive coxib plus PPI therapy and should be tested and treated for Helicobacter pylori infection. Most patients with increased cardiovascular risk will be treated with antiplatelet agents. It is not known whether co-therapy with low-dose aspirin will reduce the incidence of cardiovascular events, but it will further increase GI risk. It is currently unclear whether the risk of developing upper GI events with coxib plus aspirin is lower than it is with NSAIDs plus aspirin. However, all these patients should benefit from PPI co-therapy. Helicobacter pylori eradication should be considered as an additional therapeutic option when we want to further reduce the GI risk in specific patients. When the lower GI tract is of concern, coxib rather than NSAID therapy should be considered as the first option. Coxib therapy has better GI tolerance than NSAIDs, but patients with peptic ulcers or dyspepsia during NSAID/coxib treatment need PPI co-therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Hawkey CJ: Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000, 119: 521–535.

    Article  PubMed  CAS  Google Scholar 

  2. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 2000, 343: 1520–1528. This study showed that treatment with rofecoxib, 50 mg/d, was associated with reduced incidence of serious upper GI events and increased incidence of myocardial infarction when compared with naproxen, 500 mg twice daily, taken for a mean of 9 months.

    Article  PubMed  CAS  Google Scholar 

  3. Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000, 284: 1247–1255. When compared with NSAIDs, high-dose celecoxib (400 mg twice daily) was associated with reduced incidence of upper GI complications in patients not taking low-dose aspirin. No differences were observed in patients taking low-dose aspirin.

    Article  PubMed  CAS  Google Scholar 

  4. Schnitzer TJ, Burmester GR, Mysler E, et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004, 364: 665–674. When compared with nonselective NSAIDs, lumiracoxib, 400 mg/d, was associated with reduced incidence of upper GI complications. The differences were present in patients not taking low-dose aspirin, but there were no statistical differences in patients taking low-dose aspirin.

    Article  PubMed  CAS  Google Scholar 

  5. Lanas A, Panes J, Pique JM: Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract. Curr Pharm Des 2003, 9: 2253–2266.

    Article  PubMed  CAS  Google Scholar 

  6. Laine L, Connors LG, Reicin A, et al.: Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003, 124: 288–292. This post-hoc analysis of the VIGOR study showed that rofecoxib, 50 mg/d, was also associated with reduced risk of serious events located in the lower GI tract when compared with naproxen.

    Article  PubMed  CAS  Google Scholar 

  7. Goldstein JL, Eisen GM, Lewis B, et al.: Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005, 3: 133–141.

    Article  PubMed  Google Scholar 

  8. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999, 340: 1888–1899.

    Article  PubMed  CAS  Google Scholar 

  9. Lanas A, Perez-Aisa MA, Feu F, et al.: Investigators of the Asociacion Espanola de Gastroenterologia (AEG). A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with non-steroidal anti-inflammatory drug use. Am J Gastroenterol 2005, 100: 1685–1693.

    Article  PubMed  CAS  Google Scholar 

  10. Mamdani M, Rochon PA, Juurlink DN, et al.: Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002, 325: 624.

    Article  PubMed  CAS  Google Scholar 

  11. Laine L: Approaches to NSAID use in the high risk patient. Gastroenterology 2001, 120: 594–606.

    Article  PubMed  CAS  Google Scholar 

  12. Bresalier RS, Sandler RS, Quan H, et al.: Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352: 1092–1102. In this colonic adenoma prevention trial, long-term use of rofecoxib, 25 mg/d, was associated with increased risk of cardiovascular events when compared with placebo. The differences were observed after 18 months of therapy.

    Article  PubMed  CAS  Google Scholar 

  13. FitzGerald GA, Patrono C: The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001, 345: 433–442.

    Article  PubMed  CAS  Google Scholar 

  14. Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005, 330: 1366.

    Article  PubMed  CAS  Google Scholar 

  15. Ray WA, Stein CM, Hall K, et al.: Non-steroidal antiinflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002, 359: 118–123.

    Article  PubMed  CAS  Google Scholar 

  16. Solomon DH, Schneeweiss S, Glynn RJ, et al.: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004, 109: 2068–2073.

    Article  PubMed  CAS  Google Scholar 

  17. Garcia Rodriguez LA, Gonzalez-Perez A: Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med 2005, 3: 17.

    Article  PubMed  Google Scholar 

  18. Weil J, Colin-Jones D, Langman M, et al.: Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995, 310: 827–830.

    PubMed  CAS  Google Scholar 

  19. Lanas A, Ferrandez A: Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding. Expert Opin Drug Saf 2002, 1: 245–252.

    Article  PubMed  CAS  Google Scholar 

  20. Serrano P, Lanas A, Arroyo MT, Ferreira IJ: Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002, 16: 1945–1953.

    Article  PubMed  CAS  Google Scholar 

  21. Lanas A, Hirschowitz BI: Toxicity of NSAIDs in the stomach and duodenum. Eur J Gastroenterol Hepatol 1999, 11: 375–381.

    Article  PubMed  CAS  Google Scholar 

  22. Hunt R, Fallone C, Veldhuyzan van Zanten S, et al.: CHSG 2004 participants. Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori-an evidencebased evaluation of six topics relevant to clinical outcomes in patients evaluated for H. pylori infection. Can J Gastroenterol 2004, 18: 547–554.

    PubMed  Google Scholar 

  23. Laine L, Bombardier C, Hawkey CJ, et al.: Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002, 123: 1006–1012. Post-hoc analysis of upper GI events associated with either rofecoxib or naproxen in the VIGOR trial, according to different risk factors. Age greater than 70 years and previous ulcer history were significant risk factors. Helicobacter pylori infection was also associated with reduced GI benefit of rofecoxib over naproxen.

    Article  PubMed  CAS  Google Scholar 

  24. Abraham NS, El-Serag NB, Johnson M, et al.: National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005, 129: 1171–1178. This and other studies have shown that current GI prevention strategies in patients taking NSAIDs are being followed in only a minority of patients.

    Article  PubMed  Google Scholar 

  25. Sturkenboom MC, Burke TA, Dieleman JP, et al.: Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003, 42(Suppl 3): iii23-iii31.

    CAS  Google Scholar 

  26. Garcia Rodriguez LA, Hernandez-Diaz S: Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001, 12: 570–576.

    Article  PubMed  CAS  Google Scholar 

  27. Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352: 1071–1080. In this colonic adenoma prevention trial, long-term use of celecoxib, 200 and 400 mg twice daily, was associated with increased risk of cardiovascular events when compared with placebo. The differences were observed after 12 months of therapy.

    Article  PubMed  CAS  Google Scholar 

  28. Lanas A, Garcia Rodriguez LA, Arroyo MA, et al.: Coxibs, NSAIDs, aspirin, PPIs and the risks of upper GI bleeding in common clinical practice [abstract]. Gastroenterology 2005, 128(4,part 2): 629.

    Google Scholar 

  29. Silverstein FE, Graham DY, Senior JR, et al.: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123: 241–249.

    PubMed  CAS  Google Scholar 

  30. Hooper L, Brown TJ, Elliott R, et al.: The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004, 329: 948–957. This meta-analysis of available clinical trials analyzed the effect of different strategies in the prevention of serious upper GI events. When compared with placebo, misoprostol is associated with prevention of both endoscopic ulcers and upper GI complications, whereas PPI therapy is associated with prevention of endoscopic ulcers. Coxib therapy is associated with a 50% risk in reduction of both endoscopic ulcers and upper GI complications when compared with NSAIDs.

    Article  PubMed  CAS  Google Scholar 

  31. Lanas A: Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract. Aliment Pharmacol Ther 2004, 20: 321–331.

    Article  PubMed  CAS  Google Scholar 

  32. Rostom A, Dube C, Wells G, et al.: Prevention of NSAIDinduced gastroduodenal ulcers. Cochrane Database Syst Rev 2004, 4: 1–111.

    Google Scholar 

  33. Canadian Coordinating Office for Health Technology Assessment: Gastroduodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2004. [Report no. 12.]

    Google Scholar 

  34. Chan FK, Chung SC, Suen BY, et al.: Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001, 344: 967–973. In patients with previous ulcer bleeding, omeprazole was more effective than H. pylori eradication in the prevention of ulcer bleeding recurrence in patients taking naproxen for 6 months.

    Article  PubMed  CAS  Google Scholar 

  35. Chan FK, Hung LC, Suen BY, et al.: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002, 347: 2104–2110. In patients with previous ulcer bleeding, celecoxib, 200 mg twice daily, was associated with a similar rate of ulcer bleeding recurrence to that observed with omeprazole combined with diclofenac, 75 mg twice daily, after 6 months of therapy.

    Article  PubMed  CAS  Google Scholar 

  36. Lanas A, Bajador E, Serrano P, et al.: Nitrovasodilators, low-dose aspirin, nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000, 343: 834–839.

    Article  PubMed  CAS  Google Scholar 

  37. Goldstein JL, Howard K, McLaughlin T, et al.: The effectiveness of concomitant PPI therapy in preventing NSAID-related gastroduodenal mucosal injury. Does adherence matter? [abstract] Gastroenterology 2005, 128(4,part2): 860.

    Google Scholar 

  38. Kimmey MB, Lanas A: Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors. Aliment Pharmacol Ther 2004, 19(Suppl 1): 60–65.

    Article  PubMed  CAS  Google Scholar 

  39. Laheij RJ, Sturkenboom MC, Hassing RJ, et al.: Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292: 1955–1960.

    Article  PubMed  CAS  Google Scholar 

  40. Laine L, Harper S, Simon T, et al.: A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999, 117: 776–783.

    Article  PubMed  CAS  Google Scholar 

  41. Emery P, Zeidler H, Kvien TK, et al.: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999, 354: 2106–2111.

    Article  PubMed  CAS  Google Scholar 

  42. Cheng HF, Harris RC: Renal effects of non-steroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des 2005, 11: 1795–1804.

    Article  PubMed  CAS  Google Scholar 

  43. Spiegel BM, Chiou CF, Ofman JJ: Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis Rheum 2005, 53: 185–197.

    Article  PubMed  Google Scholar 

  44. Rahme E, Barkun A, Toubouti Y, et al.: Do proton pump inhibitors infer additional gastrointestinal protection in patients given celecoxib? A retrospective cohort study. Gastroenterology 2005, 128(4,part 2): 864.

    Google Scholar 

  45. Huang JQ, Sridhar L, Hunt RH: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002, 359: 14–22. This meta-analysis of observational studies shows that, when compared with non-H. pylori-infected patients who do not take NSAIDs, H. pylori infection is associated with increased risk of gastroduodenal ulcers and upper GI complications in patients taking NSAIDs.

    Article  PubMed  CAS  Google Scholar 

  46. Chan FK, Sung JJ, Chung SC, et al.: Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997, 350: 975–979.

    Article  PubMed  CAS  Google Scholar 

  47. Chan FK, To KF, Wu JC, et al.: Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting longterm treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002, 359: 9–13.

    Article  PubMed  CAS  Google Scholar 

  48. Hawkey CJ, Tulassay Z, Szczepanski L, et al.: Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet 1998, 352: 1016–1021. [Published erratum appears in Lancet 1998, 352:1634]

    Article  PubMed  CAS  Google Scholar 

  49. Yeomans ND, Tulassay Z, Juhasz L, et al.: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998, 338: 719–726.

    Article  PubMed  CAS  Google Scholar 

  50. Chan F, Wong V, Suen B, et al.: Effect of celecoxib on the healing of complicated gastric ulcers: a prospective double blinded randomized trial [abstract]. Gastroenterology 2005, 128: 140.

    Google Scholar 

  51. Hawkey CJ, Karrasch JA, Szczepanski L, et al.: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998, 338: 727–734.

    Article  PubMed  CAS  Google Scholar 

  52. Yeomans ND, Lanas A, Talley NJ, et al.: Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005, 22: 795–801.

    Article  PubMed  CAS  Google Scholar 

  53. Moore RA, Derry S, Makinson GT, McQuay HJ: Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005, 7: R644-R665.

    Article  PubMed  CAS  Google Scholar 

  54. Watson DJ, Harper SE, Zhao PL, et al.: Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000, 160: 2998–3003.

    Article  PubMed  CAS  Google Scholar 

  55. Cullen D, Bardhan KD, Eisner M, et al.: Primary gastroduodenal prophylaxis with omeprazole for nonsteroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998, 12: 135–140.

    Article  PubMed  CAS  Google Scholar 

  56. Hawkey C, Talley NJ, Yeomans ND, et al.: Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005, 100: 1028–1036.

    Article  PubMed  CAS  Google Scholar 

  57. Kimmey MB: Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance. Am J Med 2004, 117(Suppl 5A): 72S-78S.

    PubMed  CAS  Google Scholar 

  58. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C: Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005, 353: 2373–2383.

    Article  PubMed  CAS  Google Scholar 

  59. Lanas A, Fuentes J, Benito R, et al.: Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002, 16: 779–786.

    Article  PubMed  CAS  Google Scholar 

  60. Lai KC, Lam SK, Chu KM, et al.: Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002, 346: 2033–2038.

    Article  PubMed  CAS  Google Scholar 

  61. Lanas A, Martin-Mola E, Ponce J, et al.: Clinical strategy to prevent the gastrointestinal adverse effects of nonsteroidal anti-inflammatory agents [in Spanish]. Gastroenterol Hepatol 2003, 26: 485–502.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service of Gastroenterology, University Hospital, 50009, Zaragoza, Spain

    Angel Lanas MD, PhD

Authors
  1. Angel Lanas MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lanas, A. Prevention and treatment of NSAID-induced gastroduodenal injury. Curr Treat Options Gastro 9, 147–156 (2006). https://doi.org/10.1007/s11938-006-0033-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-006-0033-4

Keywords

Search

Navigation